549 related articles for article (PubMed ID: 10426994)
1. An activating immunoreceptor complex formed by NKG2D and DAP10.
Wu J; Song Y; Bakker AB; Bauer S; Spies T; Lanier LL; Phillips JH
Science; 1999 Jul; 285(5428):730-2. PubMed ID: 10426994
[TBL] [Abstract][Full Text] [Related]
2. NKG2D-mediated signaling requires a DAP10-bound Grb2-Vav1 intermediate and phosphatidylinositol-3-kinase in human natural killer cells.
Upshaw JL; Arneson LN; Schoon RA; Dick CJ; Billadeau DD; Leibson PJ
Nat Immunol; 2006 May; 7(5):524-32. PubMed ID: 16582911
[TBL] [Abstract][Full Text] [Related]
3. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA.
Bauer S; Groh V; Wu J; Steinle A; Phillips JH; Lanier LL; Spies T
Science; 1999 Jul; 285(5428):727-9. PubMed ID: 10426993
[TBL] [Abstract][Full Text] [Related]
4. NKG2D recruits two distinct adapters to trigger NK cell activation and costimulation.
Gilfillan S; Ho EL; Cella M; Yokoyama WM; Colonna M
Nat Immunol; 2002 Dec; 3(12):1150-5. PubMed ID: 12426564
[TBL] [Abstract][Full Text] [Related]
5. Cloning, sequencing, and cell surface expression pattern of bovine immunoreceptor NKG2D and adaptor molecules DAP10 and DAP12.
Fikri Y; Nyabenda J; Content J; Huygen K
Immunogenetics; 2007 Aug; 59(8):653-9. PubMed ID: 17530242
[TBL] [Abstract][Full Text] [Related]
6. UL16-binding proteins, novel MHC class I-related proteins, bind to NKG2D and activate multiple signaling pathways in primary NK cells.
Sutherland CL; Chalupny NJ; Schooley K; VandenBos T; Kubin M; Cosman D
J Immunol; 2002 Jan; 168(2):671-9. PubMed ID: 11777960
[TBL] [Abstract][Full Text] [Related]
7. DAP10 and DAP12 form distinct, but functionally cooperative, receptor complexes in natural killer cells.
Wu J; Cherwinski H; Spies T; Phillips JH; Lanier LL
J Exp Med; 2000 Oct; 192(7):1059-68. PubMed ID: 11015446
[TBL] [Abstract][Full Text] [Related]
8. NKG2D-DAP10 triggers human NK cell-mediated killing via a Syk-independent regulatory pathway.
Billadeau DD; Upshaw JL; Schoon RA; Dick CJ; Leibson PJ
Nat Immunol; 2003 Jun; 4(6):557-64. PubMed ID: 12740575
[TBL] [Abstract][Full Text] [Related]
9. Impairment of NK cell function by NKG2D modulation in NOD mice.
Ogasawara K; Hamerman JA; Hsin H; Chikuma S; Bour-Jordan H; Chen T; Pertel T; Carnaud C; Bluestone JA; Lanier LL
Immunity; 2003 Jan; 18(1):41-51. PubMed ID: 12530974
[TBL] [Abstract][Full Text] [Related]
10. Comparative analysis of human NK cell activation induced by NKG2D and natural cytotoxicity receptors.
André P; Castriconi R; Espéli M; Anfossi N; Juarez T; Hue S; Conway H; Romagné F; Dondero A; Nanni M; Caillat-Zucman S; Raulet DH; Bottino C; Vivier E; Moretta A; Paul P
Eur J Immunol; 2004 Apr; 34(4):961-71. PubMed ID: 15048706
[TBL] [Abstract][Full Text] [Related]
11. The activating NKG2D receptor assembles in the membrane with two signaling dimers into a hexameric structure.
Garrity D; Call ME; Feng J; Wucherpfennig KW
Proc Natl Acad Sci U S A; 2005 May; 102(21):7641-6. PubMed ID: 15894612
[TBL] [Abstract][Full Text] [Related]
12. NKG2D splice variants: a reexamination of adaptor molecule associations.
Rabinovich B; Li J; Wolfson M; Lawrence W; Beers C; Chalupny J; Hurren R; Greenfield B; Miller R; Cosman D
Immunogenetics; 2006 Apr; 58(2-3):81-8. PubMed ID: 16470377
[TBL] [Abstract][Full Text] [Related]
13. Silencing human NKG2D, DAP10, and DAP12 reduces cytotoxicity of activated CD8+ T cells and NK cells.
Karimi M; Cao TM; Baker JA; Verneris MR; Soares L; Negrin RS
J Immunol; 2005 Dec; 175(12):7819-28. PubMed ID: 16339517
[TBL] [Abstract][Full Text] [Related]
14. T cells gene-engineered with DAP12 mediate effector function in an NKG2D-dependent and major histocompatibility complex-independent manner.
Teng MW; Kershaw MH; Hayakawa Y; Cerutti L; Jane SM; Darcy PK; Smyth MJ
J Biol Chem; 2005 Nov; 280(46):38235-41. PubMed ID: 16169855
[TBL] [Abstract][Full Text] [Related]
15. Natural killer cell signaling pathways.
Vivier E; Nunès JA; Vély F
Science; 2004 Nov; 306(5701):1517-9. PubMed ID: 15567854
[TBL] [Abstract][Full Text] [Related]
16. IL-21 down-regulates NKG2D/DAP10 expression on human NK and CD8+ T cells.
Burgess SJ; Marusina AI; Pathmanathan I; Borrego F; Coligan JE
J Immunol; 2006 Feb; 176(3):1490-7. PubMed ID: 16424177
[TBL] [Abstract][Full Text] [Related]
17. Phosphatidylinositol 3-kinase activation is required to form the NKG2D immunological synapse.
Giurisato E; Cella M; Takai T; Kurosaki T; Feng Y; Longmore GD; Colonna M; Shaw AS
Mol Cell Biol; 2007 Dec; 27(24):8583-99. PubMed ID: 17923698
[TBL] [Abstract][Full Text] [Related]
18. A novel ligand for the NKG2D receptor activates NK cells and macrophages and induces tumor immunity.
Diefenbach A; Hsia JK; Hsiung MY; Raulet DH
Eur J Immunol; 2003 Feb; 33(2):381-91. PubMed ID: 12645935
[TBL] [Abstract][Full Text] [Related]
19. Interactions of human NKG2D with its ligands MICA, MICB, and homologs of the mouse RAE-1 protein family.
Steinle A; Li P; Morris DL; Groh V; Lanier LL; Strong RK; Spies T
Immunogenetics; 2001; 53(4):279-87. PubMed ID: 11491531
[TBL] [Abstract][Full Text] [Related]
20. The UL16-binding proteins, a novel family of MHC class I-related ligands for NKG2D, activate natural killer cell functions.
Sutherland CL; Chalupny NJ; Cosman D
Immunol Rev; 2001 Jun; 181():185-92. PubMed ID: 11513139
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
